Indication
For the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

Medicine details

Medicine name:
buprenorphine (Buvidal)
SMC ID:
SMC2169
Pharmaceutical company
Camurus Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Advice due date:
12 August 2019
SMC meeting date:
02 July 2019
Patient group submission deadline:
03 June 2019